3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
63
Lymphoma, Large B-Cell, Diffuse
47
Lymphoma
33
Burkitt Lymphoma
27
Lymphoma, Follicular
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Lymphoma, Non-Hodgkin
14
Neoplasms
13
Lymphoma, B-Cell
11
Lymphoma, T-Cell, Peripheral
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Hodgkin Disease
9
Lymphoma, B-Cell, Marginal Zone
8
Leukemia
8
Recurrence
6
Prostatic Neoplasms, Castration-Resistant
6
Multiple Myeloma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Neoplasm Metastasis
5
Leukemia, Biphenotypic, Acute
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoproliferative Disorders
4
Lymphoma, T-Cell
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Anaplastic
4
Immunoblastic Lymphadenopathy
4
Ovarian Neoplasms
3
Myasthenia Gravis
3
Melanoma
3
Lymphoma, AIDS-Related
3
Interventions
Cyclophosphamide
5
fludarabine
4
fludarabine phosphate
3
acalabrutinib
2
Whole-Body Irradiation
2
Tacrolimus
2
Rituximab
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
Bendamustine Hydrochloride
2
pembrolizumab
1
obinutuzumab
1
ibrutinib
1
Vincristine
1
Prednisone
1
Doxorubicin
1
CA-4948
1
Bone Marrow Transplantation
1
ARQ531
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Diseases
×
Prednisone
×
1 year
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled